Bausch + Lomb, ISTA Pharma (ISTA) Get Early HSR Termination

Bausch + Lomb and ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA), today announced that they received early termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (HSR Act), in connection with Bausch + Lomb's pending acquisition of ISTA. The early termination of the waiting period under the HSR Act satisfies one of the conditions for consummation of the transaction. The transaction, which was announced on March 26, 2012, is expected to close during the second quarter of 2012 and remains subject to certain other closing conditions, including approval by ISTA's stockholders.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Real and RE/MAX Holdings receive court approval for merger
• Sigma Lithium resumes full operations after signing TAC agreement
• Solowin Holdings marks 10 years, expands into stablecoins and AI